Generic Name and Formulations:
Droperidol 2.5mg/mL; soln for IV or IM inj.
Various generic manufacturers
Indications for Droperidol:
To reduce incidence of nausea and vomiting associated with surgical and diagnostic procedures.
Max initial dose: 2.5mg IM or slow IV; may give additional 1.25mg doses to achieve desired effect.
<2yrs: not recommended. ≥2yrs: max initial dose: 0.1mg/kg.
QT prolongation (including congenital long QT syndrome).
Perform ECG prior to administration to determine if prolonged QT interval present; if prolonged, do not administer unless treatment outweighs risks; if treating, monitor for arrhythmias: perform ECG prior to treatment and 2–3hrs after completion. Risk factors for QT prolongation: CHF, bradycardia, cardiac hypertrophy, hypokalemia, hypomagnesemia, >65yrs, alcohol abuse. Pheochromocytoma. Hepatic or renal impairment. Elderly. Debilitated. Critically ill. Labor & delivery: not recommended. Pregnancy (Cat.C). Nursing mothers.
Risk of QT prolongation with concomitant Class I and III antiarrhythmics, MAOIs, antimalarials, calcium channel blockers, benzodiazepines, volatile anesthetics, IV opiates, other drugs that prolong QT interval. Caution with drugs that induce hypokalemia, hypomagnesemia (eg, diuretics, laxatives). Additive effects with CNS depressants (eg, barbiturates, tranquilizers, opioids, general anesthetics). Possible hypertension with concomitant fentanyl citrate inj.
Hypotension, tachycardia, dysphoria, drowsiness, restlessness, hyperactivity, anxiety, QT prolonation, torsade de pointes, cardiac arrest, ventricular tachycardia, neuroleptic malignant syndrome, post-op hallucinatory episodes.
Formerly known under the brand name Inapsine.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|